Pharmaceutical composition
An object of the present invention is to provide a pharmaceutical composition which has excellent stability, disintegratability, and absorbability, is easily prepared, and contains 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative. The present invention relates to a pharmaceutical composition containing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin.
1. A pharmaceutical composition, comprising:
A 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N -methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof;
hydroxypropyl-β-cyclodextrin; and
the composition includes peaks at 5 or more diffraction angles 2θ (±0.2°) selected from the group consisting of 6.5, 7.8, 9.6, 12.4, 18.8, 21.2, 23.0, 24.5, and 26.0)(°) in powder X-ray structure diffraction.
2. The pharmaceutical composition according to claim 1 ,
wherein the composition includes peaks at diffraction angles 2θ (±0.2°) of 6.5, 7.8, 9.6, 12.4, 18.8, 21.2, 23.0, 24.5, and 26.0 (°) in powder X-ray structure diffraction.
3. The pharmaceutical composition according to claim 1 ,
wherein the composition includes peaks at chemical shift values [δ (ppm)] of 162.6, 130.4, 103.1, 82.7, 73.3, 41.9, and 19.9 in solid 13 C-NMR.
4. The pharmaceutical composition according to claim 1 ,
wherein the composition includes peaks at 5 or more absorption bands selected from the group consisting of 1663, 1352, 1225, 1156, 1032, 720, and 553 (cm −1 ) in an infrared absorption spectrum.
5. The pharmaceutical composition according to claim 1 ,
wherein hydroxypropyl-β-cyclodextrin is contained at 0.1 to 5.5 parts by mass with respect to 1 part by mass of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy -N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition according to claim 1 , further comprising:
a silicic acid derivative.
7. The pharmaceutical composition according to claim 1 , further comprising:
a cellulose derivative.
8. A pharmaceutical composition, comprising:
4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline -6-carboxamide or a pharmaceutically acceptable salt thereof;
hydroxypropyl-β-cyclodextrin;
includes peaks at 5 or more diffraction angles 2θ (±0.2°) selected from the group consisting of 6.5. 7.8, 9.6, 12.4, 18.8, 21.2, 23.0, 24.5, and 26.0 (°) in powder X-ray structure diffraction; and
wherein the pharmaceutical composition is produced by physical mixing that does not include a step in which 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N -methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof is converted into a solution state when the pharmaceutical composition is produced.
9. The pharmaceutical composition according to claim 8 ,
wherein the physical mixing is mixing or granulation.
10. The pharmaceutical composition according to claim 8 ,
wherein the composition includes peaks at diffraction angles 2θ (±0.2°) of 6.5, 7.8, 9.6, 12.4, 18.8, 21.2, 23.0, 24.5, and 26.0 (°) in powder X-ray structure diffraction.
11. The pharmaceutical composition according to claim 8 ,
wherein the composition includes peaks at chemical shift values [δ (ppm)] of 162.6, 130. 4, 103.1, 82.7, 73.3, 41.9, and 19.9 in solid 13 C-NMR.
12. The pharmaceutical composition according to claim 8 ,
wherein the composition includes peaks at 5 or more absorption bands selected from the group consisting of 1663, 1352, 1225, 1156, 1032, 720, and 553 (cm −1 ) in an infrared absorption spectrum.
13. The pharmaceutical composition according to claim 8 ,
wherein hydroxypropyl-β-cyclodextrin is contained at 0.1 to 5.5 parts by mass with respect to 1 part by mass of a mesylate salt of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide.
14. The pharmaceutical composition according to claim 8 , further comprising:
a silicic acid derivative.
15. The pharmaceutical composition according to claim 8 , further comprising:
a cellulose derivative.
16. A method for producing a pharmaceutical composition, comprising performing physical mixing of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof and hydroxypropyl-β-cyclodextrin.
17. The production method according to claim 16 ,
wherein the physical mixing is a production method that does not include a step in which 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide or a pharmaceutically acceptable salt thereof is converted into a solution state when the pharmaceutical composition is produced.
18. The production method according to claim 16 ,
wherein the physical mixing is mixing or granulation.